Programme

London Programme – Friday 21st September 2018


09:00 Arrivals & badge collection
10:00 – 10:05 Welcome, Introduction and Overview of Agenda
Dr Anna Schuh
Associate Professor, Director of Molecular Diagnostics, Honorary Consultant Haematologist, Department of Oncology, University of Oxford
10:05 – 10:30 Molecular landscape and clinical implications
Dr Anna Schuh
Associate Professor, Director of Molecular Diagnostics, Honorary Consultant Haematologist, Department of Oncology, University of Oxford
10:30 – 10:55 The tumour micro-environment
Professor Stephen Devereux
Consultant Haematologist, Kings College Hospital London & Professor of Lymphoma Biology, Kings College London
10:55 – 11:20 Changes in the paradigm of R/R CLL
Professor Peter Hillmen
Professor of Experimental Haematology and Honorary Consultant Haematologist, Leeds Teaching Hospitals NHS Trust
11:20 – 11:45 Break
11:45 – 12:10 Recent genetic insights into lymphoma
Professor Jude Fitzgibbon
Professor of Personalised Cancer Medicine, Barts Cancer institute, London
12:10 – 12:35 The many facets of PI3K-delta in immune signalling and cancer
Professor Bart Vanhaesebroeck
Professor of Cell Signalling, UCL Cancer Institute, London
12:35 – 13:00 Gene therapy for blood disorders
Dr Jenny McIntosh
Lecturer in Haematology, University College London
13:00 – 13:45 Lunch
13:45 – 14:10 Targeting DNA damage response defects in haematological malignancies
Professor Tanya Stankovic
Professor in Cancer Genetics, Institute of Cancer and Genomic Sciences, University of Birmingham
14:10 – 14:35 Clinical trials in Lymphoma
Professor Andy Pettitt
Professor of Haematology & Honorary Consultant Haematologist, University of Liverpool and Clatterbridge Cancer Centre NHS Foundation Trust, UK
14:35 – 15:00 Targeting mTOR kinase-mediated signaling pathways in CLL
Dr Alison Michie
Reader. Paul O’Gorman Leukaemia Research Centre, The University of Glasgow
15:00 Closing Remarks
Professor Tariq Enver
Director of the UCL Cancer Institute, London

 

ONC/UK/19-03/PMAR/1117f(1)
Date of preparation: June 2019

This activity is intended for medical Haematology/Oncology healthcare professionals, scientists and academics involved in the management of, and research into CAR T-cell therapy in patients with high-grade lymphoid malignancies, specifically relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), as well as those with interest in the wider treatment landscape of haematological malignancies. Data on licensed CAR-T products will be presented.